FDA Grants Fast Track Designation to R289 for LR-MDS Treatment
R289, a dual IRAK1/4 inhibitor, has received fast track status from the FDA for treating transfusion-dependent lower-risk MDS in patients with inadequate responses to prior therapies.
Related Articles
Belantamab Mafodotin Combo Could Be New SOC for Relapsed/Refractory Multiple Myeloma
Belantamab mafodotin plus bortezomib/dexamethasone improved OS over daratumumab plus bortezomib/dexamethasone in relapsed/refractory multiple myeloma.
CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer
CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.
Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
CPX-351 vs 7+3: AML-MR Mutations Drive the Benefit of CPX-351 Over 7+3
With the Oncology Brothers, Uma Borate, MD, discusses how CPX-351 demonstrates superior efficacy over 7+3 chemotherapy in treating acute myeloid leukemia with mutations in measurable…
Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies
Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.
Immune-Related Adverse Events Webinar Series #12
Join us for a virtual session where learners will hear from experts in the field in a didactic & panel case discussion format.
Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML
The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.